Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surgery or dCRT in ESCC After Neoadjuvant Chemoimmunotherapy
NCT07162506Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Nov 2025
- Primary completion
- Aug 2027
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab, paclitaxel and carboplatin in Esophageal Squamous Cell Carcinoma (ESCC) (2 cohorts), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Disease-Free Survival up to 3 years. Started Nov 2025; status: recruiting.
02
Drugs
camrelizumabpaclitaxelcarboplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07162506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07162506.